Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Alexandria

142 clinical trials in Alexandria, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Alexandria at a glance
142
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

142 trials in Alexandria

Open in trial search

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A Phase 3 Study of Sapablursen Compared with Placebo in Adults with Polycythemia Vera

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sapablursen
  • Sponsor:Deciphera Pharmaceuticals Inc.

Phase 1/2 Study Evaluating Safety and Activity of GSK5926371 in Adults with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

JNJ-79635322 versus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma After at Least 3 Prior Treatments

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Janssen Cilag International

Neoplasm

Recruiting

Volrustomig in Patients with Unresectable Pleural Mesothelioma and Esophageal Squamous Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Cisplatin
  • Sponsor:AstraZeneca AB

A study of PM54 and pembrolizumab in adults with advanced cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Pharma Mar S.A.

Study of glofitamab, obinutuzumab and tocilizumab in patients with mantle cell lymphoma relapsed or refractory after CAR‑T therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:Fondazione Italiana Linfomi Ets

A study to compare glofitamab against a drug combination for patients with relapsed or refractory mantle cell lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:F. Hoffmann-La Roche AG

A study to evaluate the effectiveness of R2R01 in preventing acute kidney injury in patients at high risk following heart surgery.

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:R2R01
  • Sponsor:River 2 Renal Corp.

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Alexandria

What the registry says about research in the country

01 Hematologic Oncology

Groundbreaking research focusing on blood cancers and related disorders, including studies on innovative treatments for lymphoma, leukemia, and multiple myeloma. Clinical trials are evaluating novel therapeutic combinations and targeted approaches.

  • Diffuse Large B-Cell Lymphoma
  • Acute Myeloid Leukemia
  • Follicular Lymphoma

Investigations include immunotherapy combinations and maintenance strategies for improved patient outcomes.

02 Respiratory Medicine

Studies focusing on preventing and treating respiratory infections and conditions, with particular emphasis on vulnerable populations. Research includes vaccine development and therapeutic interventions.

  • Respiratory Syncytial Virus
  • Upper Respiratory Tract Infections
  • Lung Cancer

Trials are exploring novel treatments and preventive strategies for respiratory conditions.

03 Cardiovascular Research

Important studies in heart failure prevention and treatment, investigating new therapeutic combinations and strategies to reduce cardiovascular risks in high-risk populations.

  • Heart Failure Prevention
  • Cardiovascular Risk Management

Research focuses on innovative drug combinations to prevent heart failure events and improve outcomes.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.